A Randomised, Double-blind, Placebo-controlled, and Single Dose-escalation Trial of AGS-009 Administered in Subjects With Systemic Lupus Erythematosus.

Trial Profile

A Randomised, Double-blind, Placebo-controlled, and Single Dose-escalation Trial of AGS-009 Administered in Subjects With Systemic Lupus Erythematosus.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2012

At a glance

  • Drugs AGS 009 (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Jun 2012 Results presented at the 13th Annual Congress of the European League Against Rheumatism.
    • 07 Jun 2012 Results have been presented at EULAR-2012 according to an Argos Therapeutics media release.
    • 27 Jan 2012 Actual end date (Dec 2011 ) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top